Health & Fitness
Health and Fitness
Health and Fitness
Tue, February 3, 2009
Mon, February 2, 2009 CytRx Corporation to Present at the 11th Annual BIO CEO & Investor Conference
LOS ANGELES--([ BUSINESS WIRE ])--CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced that Steven A. Kriegsman, CytRx President and Chief Executive Officer, will present at the 11th Annual BIO CEO & Investor Conference on Tuesday, February 10, 2009 at 10:30 a.m. Eastern time (7:30 a.m. Pacific time). The conference will be held at The Waldorf-Astoria Hotel in New York City.
The CytRx presentation will provide a corporate update, including a discussion of the Company's 2009 milestones aimed at advancing the development of its drug candidate assets. A webcast and audio archive of the presentation will be available at [ www.cytrx.com ] and a replay of the webcast will also be available on the Company's Web site for 90 days.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics. The CytRx drug development pipeline includes programs in clinical development for cancer indications, including tamibarotene in a registration study for the treatment of acute promyelocytic leukemia (APL). CytRx is developing two drug candidates based on its industry-leading molecular chaperone technology, which aims to repair or degrade misfolded proteins associated with disease. The Company owns and operates a research and development facility in San Diego. CytRx also maintains a 45% equity interest in publicly traded RXi Pharmaceuticals, Inc. (NASDAQ:RXII). For more information on the Company, visit [ www.cytrx.com ].
About the BIO CEO & Investor Conference
The BIO CEO & Investor Conference is the largest independent investor conference focused solely on publicly-traded biotechnology companies. The meeting attracts institutional investors, industry analysts, and senior biotechnology executives. In addition, the BIO CEO & Investor Conference draws business development executives from leading global pharmaceutical and mature biotechnology companies. To learn more about the BIO CEO & Investor Conference, including registration and program information, visit [ http://ceo.bio.org ]. Registration is complimentary for qualified investors and credentialed members of the media.
About BIO
BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties described in CytRx's Form 10-Q for the quarter ended September 30, 2008 and other recently filed SEC documents, such as its most recent annual report on Form 10-K. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
